

ABSTRACT

INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE

The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ≥ 0.5 mg naloxone HCl dissolved in an application fluid of a volume of ≤ 250 μ l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

[No Figure]